thyroxine has been researched along with Carcinoma, Non-Small Cell Lung in 13 studies
Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.
thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "0%) patients received levothyroxine for hypothyroidism, 24 (8." | 5.30 | Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. ( Chen, W; Cheng, Y; Han, B; Jin, F; Li, K; Luo, Y; Nan, K; Shi, J; Shi, Y; Si, X; Wang, H; Wang, M; Wang, Q; Wang, X; Wang, Z; Zhang, L; Zhang, X, 2019) |
| "Upon initiating treatment with selpercatinib, athyreotic patients developed clinical hypothyroidism with approximately 60% lower T3 levels despite adequate levothyroxine supplementation, whereas in patients with NSCLC, who retain a normal thyroid, selpercatinib resulted in a more attenuated reduction in serum T3, which was dose-dependent." | 4.12 | Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. ( Bianco, AC; Boucai, L; Drilon, A; Fagin, JA; Krishnamoorthy, GP; Rudin, CM; Salas-Lucia, F; Sherman, E, 2022) |
| "Blocking the PD-1 pathway induces immune-related adverse events (irAEs) which often involve the thyroid gland (thyroid irAEs)." | 1.51 | Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. ( Fujii, T; Hishizawa, M; Inagaki, N; Kawaguchi-Sakita, N; Kim, YH; Kitamura, M; Kitawaki, T; Matsumoto, S; Nomura, M; Otsuka, A; Saito, R; Sakamori, Y; Sone, M; Taura, D; Yamasaki, T; Yamauchi, I; Yasoda, A, 2019) |
| " Levothyroxine dosing required doubling in three patients with a known history of hypothyroidism." | 1.46 | Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms. ( Bornschlegl, S; Delivanis, DA; Dietz, AB; Gustafson, MP; Kottschade, L; Merten, MM; Ryder, M; Withers, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (61.54) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, CC | 1 |
| Huang, TY | 1 |
| Chu, HR | 1 |
| De Luca, R | 1 |
| Candelotti, E | 1 |
| Huang, CH | 1 |
| Yang, YSH | 1 |
| Incerpi, S | 1 |
| Pedersen, JZ | 1 |
| Lin, CY | 1 |
| Huang, HM | 1 |
| Lee, SY | 1 |
| Li, ZL | 1 |
| ChangOu, CA | 1 |
| Li, WS | 1 |
| Davis, PJ | 2 |
| Lin, HY | 2 |
| Whang-Peng, J | 1 |
| Wang, K | 1 |
| Boucai, L | 1 |
| Salas-Lucia, F | 1 |
| Krishnamoorthy, GP | 1 |
| Sherman, E | 1 |
| Rudin, CM | 1 |
| Drilon, A | 1 |
| Bianco, AC | 1 |
| Fagin, JA | 1 |
| Funazo, TY | 1 |
| Nomizo, T | 1 |
| Ozasa, H | 1 |
| Tsuji, T | 1 |
| Yasuda, Y | 1 |
| Yoshida, H | 1 |
| Sakamori, Y | 2 |
| Nagai, H | 1 |
| Hirai, T | 1 |
| Kim, YH | 2 |
| Uppal, NN | 1 |
| Wanchoo, R | 1 |
| Barnett, R | 1 |
| Sinha, A | 1 |
| Jhaveri, KD | 1 |
| Matsuoka, N | 1 |
| Tsuji, K | 1 |
| Ichihara, E | 1 |
| Hara, T | 1 |
| Fukushima, K | 1 |
| Toma, K | 1 |
| Kitamura, S | 1 |
| Inagaki, K | 1 |
| Sugiyama, H | 1 |
| Wada, J | 1 |
| Delivanis, DA | 1 |
| Gustafson, MP | 1 |
| Bornschlegl, S | 1 |
| Merten, MM | 1 |
| Kottschade, L | 1 |
| Withers, S | 1 |
| Dietz, AB | 1 |
| Ryder, M | 1 |
| Yu, H | 1 |
| Liu, M | 1 |
| Qiu, H | 1 |
| Yang, K | 1 |
| Si, X | 1 |
| Zhang, L | 1 |
| Wang, H | 1 |
| Zhang, X | 2 |
| Wang, M | 1 |
| Han, B | 1 |
| Li, K | 1 |
| Wang, Q | 1 |
| Shi, J | 1 |
| Wang, Z | 1 |
| Cheng, Y | 1 |
| Shi, Y | 1 |
| Chen, W | 1 |
| Wang, X | 1 |
| Luo, Y | 1 |
| Nan, K | 1 |
| Jin, F | 1 |
| Peiró, I | 1 |
| Palmero, R | 1 |
| Iglesias, P | 1 |
| Díez, JJ | 1 |
| Simó-Servat, A | 1 |
| Marín, JA | 1 |
| Jiménez, L | 1 |
| Domingo-Domenech, E | 1 |
| Mancho-Fora, N | 1 |
| Nadal, E | 1 |
| Villabona, C | 1 |
| Yamauchi, I | 1 |
| Yasoda, A | 1 |
| Matsumoto, S | 1 |
| Nomura, M | 1 |
| Otsuka, A | 1 |
| Yamasaki, T | 1 |
| Saito, R | 1 |
| Kitamura, M | 1 |
| Kitawaki, T | 1 |
| Hishizawa, M | 1 |
| Kawaguchi-Sakita, N | 1 |
| Fujii, T | 1 |
| Taura, D | 1 |
| Sone, M | 1 |
| Inagaki, N | 1 |
| Wu, Y | 1 |
| Lv, J | 1 |
| Li, X | 1 |
| Ma, L | 1 |
| Nong, J | 1 |
| Zhang, H | 1 |
| Qin, N | 1 |
| Zhang, Q | 1 |
| Shi, G | 1 |
| Yang, X | 1 |
| Wang, J | 1 |
| Zhang, S | 1 |
| Mousa, SA | 1 |
| Yalcin, M | 1 |
| Bharali, DJ | 1 |
| Meng, R | 1 |
| Tang, HY | 1 |
| Davis, FB | 1 |
| Wawrzyńska, L | 1 |
| Caban, P | 1 |
| Rudziński, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Single-arm Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced Non-small Cell Lung Cancer With EGFR 21L858R Mutation[NCT06102928] | 30 participants (Anticipated) | Interventional | 2023-10-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thyroxine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects a | 2019 |
[Examination of thyroxine conversion to triiodothyronine in the lungs (preliminary report)].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Emphysema; Euthyroid Sick Syndromes; Humans; In V | 1996 |
11 other studies available for thyroxine and Carcinoma, Non-Small Cell Lung
| Article | Year |
|---|---|
Heteronemin and tetrac derivatives suppress non-small cell lung cancer growth via ERK1/2 inhibition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; | 2022 |
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase.
Topics: Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Humans; Hypothyroidism; Iodide Peroxidase | 2022 |
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological; B7-H1 Antigen; Biomarkers, Tum | 2019 |
Hyponatremia in a Patient With Cancer.
Topics: Adrenal Insufficiency; Adrenocorticotropic Hormone; Aged; Antibodies, Monoclonal, Humanized; Antineo | 2020 |
Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Biopsy; Carcinoma, Non-Smal | 2020 |
Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autoantibo | 2017 |
Urinary and Plasma Cell-Free DNA Comparison for Lung Cancer Patients Treated With Epidermal Growth Factor Receptor-Thyroxine Kinase Inhibitors.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Cell-Free Nucleic Acids; Cohort Studies; Cyclin-Dependent Kin | 2019 |
Thyroid dysfunction induced by nivolumab: searching for disease patterns and outcomes.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Hodgkin D | 2019 |
Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxygluco | 2019 |
Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male | 2019 |
Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and its growth in xenografts.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioa | 2012 |